Another major buy was in INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), with ARK purchasing 191,705 shares for around $2.18 million through its ARKK ETF. Similar to CRISPR, INTELLIA has seen increased ...

NtRON Bio announced today, following its recent U.S. patent application related to colorectal cancer using the IMPA™ phage engineering technology, it has now completed the filing of two patents for a ...

Researchers demonstrate the active role methyl groups play in silencing genes, demonstrating the therapeutic potential of ...

On the buying side, ARK’s most notable investment was in CRISPR Therapeutics AG (NASDAQ:CRSP), acquiring 188,879 shares with a total dollar value of $10,259,907. This purchase indicates a strong ...

5 latest biotechnology breakthroughs, from genome sequencing to microbiome manipulation, revolutionizing medicine, ...

Scientists at MD Anderson created PreCiSE, a CRISPR tool that maps genes controlling natural killer (NK) cells. Editing these ...

There were more than 48,000 organ transplants in the U.S. in 2024, a 3.3% increase from 2023, according to Organ Procurement ...

Lund University scientists report that repetitive DNA once dismissed as “junk” plays an active role in human brain ...

Explore Cathie Wood's investment strategy at Ark Invest. Discover her top stock picks like Tesla and CRISPR, and her focus on ...

Chocolate makers are racing to secure the future of cocoa amid climate threats and disease outbreaks. From lab-grown cocoa ...

Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of ...

For decades, large stretches of human DNA were dismissed as "junk" and considered to serve no real purpose. In a new study ...